Mark Bustoros

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4622917/publications.pdf

Version: 2024-02-01

39 papers	1,238 citations	516215 16 h-index	395343 33 g-index
39 all docs	39 docs citations	39 times ranked	2135 citing authors

#	Article	IF	Citations
1	Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematology,the, 2022, 9, e340-e349.	2.2	27
2	Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nature Communications, 2022, 13, .	5.8	11
3	Placental extracellular vesiclesâ€“associated microRNA-519c mediates endotoxin adaptation in pregnancy. American Journal of Obstetrics and Gynecology, 2021, 225, 681.e1-681.e20.	0.7	15
4	Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clinical Cancer Research, 2021, 27, 5195-5212.	3.2	26
5	Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes. Blood, 2021, 138, 723-723.	0.6	0
6	Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Response to Immunotherapy in Patients with High-Risk Smoldering Myeloma. Blood, 2021, 138, 330-330.	0.6	2
7	An Overview of Selected Rare B-Cell Lymphoproliferative Disorders: Imaging, Histopathologic, and Clinical Features. Cancers, 2021, 13, 5853.	1.7	4
8	High Prevalence of Monoclonal Gammopathy in a Population at Risk: The First Results of the Promise Study. Blood, 2021, 138, 152-152.	0.6	3
9	Regular Aspirin Use and Mortality in Multiple Myeloma Patients. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.EPI-21-0946-E.2021.	1.1	1
10	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nature Communications, 2020, 11, 2996.	5.8	98
11	Genome instability in multiple myeloma. Leukemia, 2020, 34, 2887-2897.	3.3	63
12	Genomic Landscape of WaldenstrÃ¶m Macroglobulinemia and Its Impact on Treatment Strategies. Journal of Clinical Oncology, 2020, 38, 1198-1208.	0.8	103
13	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nature Cancer, 2020, 1, 493-506.	5.7	209
14	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. Journal of Clinical Oncology, 2020, 38, 2380-2389.	0.8	110
15	A Next Generation Liquid Biopsy Approach for Multiple Myeloma. Blood, 2020, 136, 33-33.	0.6	0
16	Reply to F.D. Leonard. Journal of Clinical Oncology, 2019, 37, 2701-2702.	0.8	0
17	Progression Risk Stratification of Asymptomatic WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2019, 37, 1403-1411.	0.8	65
18	Bone marrow biopsy in lowâ€risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. American Journal of Hematology, 2019, 94, E146-E149.	2.0	11

#	Article	IF	Citations
19	Progression risk stratification of Asymptomatic WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e38-e39.	0.2	0
20	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e27.	0.2	0
21	Bone marrow niche in multiple myeloma and its precursor states. HemaSphere, 2019, 3, 121-123.	1.2	1
22	The PROMISE Study: A Nationwide Project for Predicting the Progression of Developing Myeloma in a High-Risk Screened Population. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e310.	0.2	1
23	Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression.. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e5-e6.	0.2	1
24	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. Blood, 2019, 134, 4172-4172.	0.6	6
25	A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety. Blood, 2019, 134, 1898-1898.	0.6	6
26	Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nature Communications, 2018, 9, 1691.	5.8	153
27	Profiling of circulating exosomal miRNAs in patients with WaldenstrÃ¶m Macroglobulinemia. PLoS ONE, 2018, 13, e0204589.	1.1	17
28	Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood, 2018, 132, 2608-2612.	0.6	29
29	Advancements in Nanomedicine for Multiple Myeloma. Trends in Molecular Medicine, 2018, 24, 560-574.	3.5	23
30	A Rare Case of Composite Dural Extranodal Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Frontiers in Neurology, 2018, 9, 267.	1.1	16
31	Blocking IFNAR1 inhibits multiple myelomaâ€“driven Treg expansion and immunosuppression. Journal of Clinical Investigation, 2018, 128, 2487-2499.	3.9	80
32	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. Blood, 2018, 132, 749-749.	0.6	6
33	Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma. Blood, 2018, 132, 2603-2603.	0.6	1
34	Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. Blood, 2018, 132, 804-804.	0.6	42
35	Established and Novel Prognostic Biomarkers in Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 548-560.	1.8	21
36	Established and Novel Prognostic Biomarkers in Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 548-560.	1.8	12

#	Article	IF	Citations
37	Adult Primary Spinal Epidural Extraosseous Ewingâ€™s Sarcoma: A Case Report and Review of the Literature. Case Reports in Neurological Medicine, 2016, 2016, 1-8.	0.3	9
38	Patient-Specific Screening Using High-Grade Glioma Explants to Determine Potential Radiosensitization by a TGF-Î² Small Molecule Inhibitor. Neoplasia, 2016, 18, 795-805.	2.3	35
39	Traumatic brain injury and subsequent glioblastoma development: Review of the literature and case reports. , 2016, 7, 78.		31